Latest Adult stem cell Stories

SACRAMENTO, Calif., April 19, 2012 /PRNewswire/ -- SynGen Inc. ("SynGen" or the "Company"), a Regenerative Medicine device company focused on the development of next generation stem cell harvesting systems, announced today that it has completed a $5 million Series A preferred stock financing with Bay City Capital, LLC (BCC). Under the terms of the transaction, BCC will appoint two representatives to SynGen's board of directors. "We are delighted to have the opportunity to work with...

The Texas Medical Board has approved new rules regulating adult stem cell therapies similar to the ones used to treat Governor Rick Perry last summer, the Associated Press (AP) reported on Friday. The rules were drafted by the state board, which licenses and disciplines doctors, at the request of Houston's Dr. Stanley Jones, the same man who in July 2011 injected Perry with the governor's own stem cells in order to help him recover from a back injury, Nathan Koppel of the Wall Street...

A team of researchers has discovered a way to boost the survival time of fat grafts in breast reconstruction, overcoming a major problem in a minimally invasive procedure that in many ways seems an ideal alternative to painful reconstructive surgery. “Consequently, this will lead to improved long-term cosmetic results for these patients,” said Dr. Pietro Gentile, a reconstructive surgeon at the University of Tor Vergata in Rome and lead author of the study, which is published in the...

In spite of considerable research efforts around the world, we still do not know the determining factors that confer stem cells their main particular features: capacity to self-renew and to divide and proliferate. The scientist Jordi Casanova, head of the “Morphogenesis in Drosophila” lab at IRB Barcelona and CSIC research professor, proposes in an article in the journal Embo Reports that we may be working from an incorrect angle. Casanova’s notion is that stem cells emerge not because...

MONT-SAINT-GUIBERT, Belgium, April 12, 2012 /PRNewswire/ -- The Belgian biotechnology company Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces that it has been granted Good Manufacturing Practice (GMP) Certification for its new production facilities in Mont-Saint-Guibert. Certification was granted by the Federal Agency for Medicines and Health Products (FAMHP),...

RANCHO CORDOVA, Calif., April 11, 2012 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today that China's State Food and Drug Administration (SFDA) has approved the registration of the Company's BioArchive(®) System (BioArchive), enabling its direct commercial sale by the Company into the People's Republic of China. "This is an essential step in our strategy to be the...

JUPITER, Fla., April 11, 2012 /PRNewswire/ --BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCQB: BRTX), a life sciences company focused on cellular therapies for various personal medical applications, announced today it has closed on the previously announced license agreement with Regenerative Sciences, LLC for the licensing of a technique used for the treatment of bulging and herniated discs. This treatment encompasses a novel way of cell culturing and includes a...

NEW YORK, April 10, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC.PK) announced today that the Company has signed a technology licensing agreement with Stem Cells 21 of Thailand, http://www.StemCells21.com. Stem Cells 21 is led by Dr. Chatchai Sribundit MD, a fellow of the College of Anti-ageing Medicine and a member of the National Olympic Committee and Mr. Paul Collier, the Managing Director for the Stem Cells 21. They have been in the cellular...

JUPITER, Fla., April 10, 2012 /PRNewswire/ -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCQB: BRTX), a life sciences company focused on cellular therapies for various personal medical applications, announced today that it has completed multiple rounds of private financing in 2012 totaling approximately $2,100,000. A total of approximately $1,600,000 was received as debt financing and an additional $500,000 was raised as equity. Pursuant to the equity and note...

Post-doctoral researcher David Fluri and Professor Peter Zandstra at the University of Toronto's Institute of Biomaterials and Biomedical Engineering (IBBME) have developed a unique new technique for growing stem cells that may make possible cost-effective, large-scale stem cell manufacturing and research. Although stem cells are widely used for the testing of new drugs, researchers have always faced difficulties manufacturing enough viable cells from a culture. Typically, stem cells are...